Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FR054 is an inhibitor of the Hexosamine Biosynthetic Pathway (HBP) enzyme PGM3, with a remarkable anti-breast cancer effect. FR054 induces in different breast cancer cells a dramatic decrease in cell proliferation and survival.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 39.00 | |
10 mg | In stock | $ 59.00 | |
25 mg | In stock | $ 94.00 | |
50 mg | In stock | $ 128.00 | |
100 mg | In stock | $ 198.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 43.00 |
Description | FR054 is an inhibitor of the Hexosamine Biosynthetic Pathway (HBP) enzyme PGM3, with a remarkable anti-breast cancer effect. FR054 induces in different breast cancer cells a dramatic decrease in cell proliferation and survival. |
In vivo | The effect of FR054 occurs through PGM3 inhibition instead of other off-target effects. FR054 (0.5-1 mM, 24-48 h) induces an early proliferation arrest followed by a marked cell death increase in breast cancer cells and induces apoptosis. FR054 (250?μM, 24 h) treatment efficiently affects both N- and O-glycosylation levels in MDA-MB-231 cells. FR054 induces endoplasmic reticulum stress and ROS-dependent apoptotic cell death [1]. |
Molecular Weight | 329.3 |
Formula | C14H19NO8 |
CAS No. | 35954-65-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 75 mg/mL (227.76 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FR054 35954-65-5 Others TNBC HBP inhibit FR-054 FR 054 Negative Cancer Inhibitor Breast Triple PGM3 inhibitor